Efficacy and safety of semaglutide for weight management: evidence from the STEP program

References

• Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45(3):511–520.
   PubMed Web of Science ®Google Scholar
• Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–1061.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity and overweight. 2021 [cited 2022 Jul 21]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
   Google Scholar
• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;(360):1–8.
   Google Scholar
• Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–1096.
   PubMed Web of Science ®Google Scholar
• Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23(4):591–601.
   PubMed Web of Science ®Google Scholar
• Saunders KH, Umashanker D, Igel LI, et al. Obesity pharmacotherapy. Med Clin North Am. 2018;102(1):135–148.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
   PubMed Web of Science ®Google Scholar
• Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875–E891.
   PubMed Web of Science ®Google Scholar
• Rose F, Bloom S, Tan T. Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years. Expert Opin Drug Discov. 2019;14(11):1151–1159.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
   PubMed Web of Science ®Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–2350.
   PubMed Web of Science ®Google Scholar
• Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403(2):261–280.
   PubMed Web of Science ®Google Scholar
• Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280–1290.
   PubMed Web of Science ®Google Scholar
• Sharma S, Mells JE, Fu PP, et al. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One. 2011;6(9):e25269.
   PubMed Web of Science ®Google Scholar
• Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol. 2010;92(3):442–462.
   PubMed Web of Science ®Google Scholar
• Wang XC, Gusdon AM, Liu H, et al. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol. 2014;20(40):14821–14830.
   PubMed Web of Science ®Google Scholar
• Lee J, Hong S-W, Rhee E-J, et al. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab J. 2012;36(4):262–267.
   PubMedGoogle Scholar
• Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885–R895.
   PubMed Web of Science ®Google Scholar
• Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279–S284.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008;5(2):73–94.
   PubMedGoogle Scholar
• US Food and Drug Administration. Adlyxin highlights of prescribing information. 2016 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471orig1s000lbl.pdf
   Google Scholar
• US Food and Drug Administration. Byetta® highlights of prescribing information. 2009 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf
   Google Scholar
• US Food and Drug Administration. Bydureon® highlights of prescribing information. 2018 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf
   Google Scholar
• US Food and Drug Administration. Saxenda® highlights of prescribing information. 2014 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf
   Google Scholar
• US Food and Drug Administration. Tanzeum highlights of prescribing information. 2017 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125431s019lbl.pdf
   Google Scholar
• US Food and Drug Administration. Trulicity highlights of prescribing information. 2017 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s007s008lbl.pdf
   Google Scholar
• US Food and Drug Administration. Wegovy highlights of prescribing information. 2021 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
   Google Scholar
• US Food and Drug Administration. Rybelsus® highlights of prescribing information. 2019 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
   Google Scholar
• US Food and Drug Administration. Ozempic® highlights of prescribing information. 2017 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
   Google Scholar
• US Food and Drug Administration. Victoza® highlights of prescribing information. 2017 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf
   Google Scholar
• Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497–504.
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380.
   PubMed Web of Science ®Google Scholar
• Marbury TC, Flint A, Jacobsen JB, et al. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381–1390.
   PubMed Web of Science ®Google Scholar
• Kalra S, Sahay R. A review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus. Diabetes Ther. 2020;11(9):1965–1982.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem compound summary for CID 56843331, semaglutide. 2022 [cited 2022 Jul 21]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Semaglutide
   Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251.
   PubMed Web of Science ®Google Scholar
• Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–762.
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984.
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Batterham RL, Bhatt M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083–2091.
   PubMed Web of Science ®Google Scholar
• American Heart Association. AHA names top heart disease and stroke research advances of 2021. 2021 [cited 2022 July 21]. Available from: https://www.heart.org/en/around-the-aha/aha-names-top-heart-disease-and-stroke-research-advances-of-2021
   Google Scholar
• Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
   PubMed Web of Science ®Google Scholar
• Wharton S, Astrup A, Endahl L, et al. Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. Int J Obes (Lond). 2021;45(5):923–933.
   PubMed Web of Science ®Google Scholar
• Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020;45(Suppl 1):43–60.
   PubMed Web of Science ®Google Scholar
• Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14–19.
   Web of Science ®Google Scholar
• Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care. 2013;36(Suppl 2):S245–S252.
   PubMed Web of Science ®Google Scholar
• Roshanov PS, Dennis BB. Incretin-based therapies are associated with acute pancreatitis: meta-analysis of large randomized controlled trials. Diabetes Res Clin Pract. 2015;110(3):e13–e17.
   PubMed Web of Science ®Google Scholar
• Nreu B, Dicembrini I, Tinti F, et al. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinol. 2020; Online ahead of print. DOI:10.23736/S0391-1977.20.03219-8.
   PubMed Web of Science ®Google Scholar
• Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017;40(7):839–848.
   PubMed Web of Science ®Google Scholar
• Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012;18(4):472–477.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Nesina highlights of prescribing information. 2015 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022271s007lbl.pdf
   Google Scholar
• US Food and Drug Administration. Onglyza® highlights of prescribing information. 2015 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022350s018lbl.pdf
   Google Scholar
• US Food and Drug Administration. Januvia® highlights of prescribing information. 2011 [cited 2022 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021995s019lbl.pdf
   Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107–139.
   PubMed Web of Science ®Google Scholar
• Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12(12):1347–1352.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care. 2019;42(10):1912–1920.
   PubMed Web of Science ®Google Scholar
• He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513–519.
   PubMed Web of Science ®Google Scholar
• Woronow D, Chamberlain C, Niak A, et al. Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food and Drug Administration. JAMA Intern Med. 2022;182(10):1104–1106.
   PubMed Web of Science ®Google Scholar
• Faillie JL, Yu OH, Yin H, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474–1481.
   PubMed Web of Science ®Google Scholar
• Cote GJ, Grubbs EG, Hofmann MC. Thyroid C-cell biology and oncogenic transformation. Recent Results Cancer Res. 2015;204:1–39.
   PubMedGoogle Scholar
• American Thyroid Association. Medullary thyroid cancer. 2020 [cited 2022 Jul 21]. Available from: https://www.thyroid.org/wp-content/uploads/patients/brochures/medullary-thyroid-cancer-brochure.pdf
   Google Scholar
• Abd El Aziz M, Cahyadi O, Meier JJ, et al. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22(4):699–704.
   PubMed Web of Science ®Google Scholar
• Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016;387(10031):1947–1956.
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
   PubMed Web of Science ®Google Scholar
• Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–150.
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Telem DA, Kushner RF, et al. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–887.
   PubMed Web of Science ®Google Scholar
• Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N Engl J Med. 2014;370(21):2002–2013.
   PubMed Web of Science ®Google Scholar
• Maciejewski ML, Arterburn DE, Van Scoyoc L, et al. Bariatric surgery and long-term durability of weight loss. JAMA Surg. 2016;151(11):1046–1055.
   PubMed Web of Science ®Google Scholar
• Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–1576.
   PubMed Web of Science ®Google Scholar